Brainstorm Cell (BCLI) Stock Analysis: AI Score & Alternative Data
BCLI alt-data: web traffic climbing, headcount lagging
Is Brainstorm Cell a buy right now? The alternative data says hold. This BCLI stock analysis is built on the 25+ alternative data signals AltIndex tracks on Brainstorm Cell every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 44/100: a Hold. The stock trades at $0.80 with a $8M market cap.
The bullish side of the 90-day ledger: web traffic up 14.2% to 5K monthly visits, and sentiment up 203.0% to 100/100. The drag: headcount (according to LinkedIn) down 6.7% to 28 employees. That tension is what keeps the score mid-range.
BCLI’s broader alt-data profile also covers X followers (5K). Every signal links to its own page with full history, the BCLI technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on BCLI is just below.
Brainstorm Cell AI Stock Analysis
Brainstorm Cell is a biotechnology company focused on developing innovative cell therapies for various neurodegenerative diseases. The company is dedicated to discovering and providing treatment options that target critical unmet medical needs.
Analysis generated October 3, 2026.
Recent Brainstorm Cell Stock Alerts
|
Brainstorm Cell | October 14 Price is down by -7.9% in the last 24h. |
|
Brainstorm Cell | October 13 Price is down by -10% in the last 24h. |
|
Brainstorm Cell | October 12 Price is down by -8.4% in the last 24h. |
|
Brainstorm Cell | October 8 Price is up by 6.7% in the last 24h. |
Brainstorm Cell Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 5K | 14.2% | |
| Job Posts | 0 | N/A | |
| LinkedIn Employees | 28 | 6.7% | |
| Employee Recommend | 0 | N/A | |
| Business Outlook | 0 | N/A | |
| Sentiment | 100 | 203.0% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 1 | 0% | |
| Stocktwits Mentions | 10 | 64.3% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 6K | 0% | |
| X Followers | 5K | 0% | |
| Facebook Followers | 4K | 0% | |
| Facebook Engagement | 0 | N/A |
About Brainstorm Cell (BCLI)
Brainstorm Cell Therapeutics Inc., a biotechnology company, is dedicated to the development and commercialization of autologous cell therapies for the treatment of neurodegenerative diseases. The company is headquartered in New York, New York.
| Price | $0.80 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $8M |
| Year Range | $0 – $1 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Brainstorm Cell News
View more → |
BrainStorm Executive Leadership to Participate in DUPHAT 2026; Executive Chairman Peter J. Pitts Invited to Deliver Two Keynote Addresses and Moderate Panel SessionsAugust 24 - PRNewswire |
 |
BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 14 - PRNewswire |
Corporate Updates – NurExone appoints Mr. David Stolick to the Board of DirectorsJuly 28 - GlobeNewswire |
|
Stem Cell Collaboration and Licensing Deals Report 2010-2026: A Clear Insight into How Deal Terms Vary by Therapy Type, Development Stage, and Partner ProfileJuly 21 - GlobeNewswire |
|
 |
Huntington's Disease Market Poised for Significant Growth at a CAGR of 14% During the Forecast Period (2026-2036) Amid Advancements in Disease-Modifying Therapies | DelveInsightJune 25 - PRNewswire |
See Brainstorm Cell’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for BCLI, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREEBrainstorm Cell Earnings & Financial Performance
View all earnings →Brainstorm Cell Insider Trading Activity
View all →| Lebovits Chaim filed to sell 80,960 shares at $0.0. Oct 1 '24 |
| Lebovits Chaim filed to sell 1,186,865 shares at $0.0. Sep 30 '24 |
| Dagher Ibrahim B. filed to sell 0 shares at $0.0. Jul 19 '24 |
| Lebovits Chaim filed to sell 1,164,865 shares at $0.0. May 28 '24 |
| Lebovits Chaim filed to sell 1,149,865 shares at $0.0. May 22 '24 |
Brainstorm Cell Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Brainstorm Cell
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
Senti BiosciencesSNTI |
$0.26 8.6% | $8M | 40 |
 |
Bolt BiotherapeuticsBOLT |
$4.24 6.5% | $8M | 46 |
 |
CollPlant BiotechnologiesCLGN |
$3.68 10.9% | $8M | 41 |
 |
SoligenixSNGX |
$0.36 4.2% | $7M | 40 |
 |
NKGen BiotechNKGN |
$0.01 0.0% | $8M | 46 |
Explore Brainstorm Cell Data
Frequently Asked Questions: Brainstorm Cell (BCLI)
Brainstorm Cell has an AltIndex AI Score of 44/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
44/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Brainstorm Cell (BCLI) stock is $0.80 with a market cap of $8M.
As of today, Brainstorm Cell’s PE (Price to Earnings) ratio is —.
View the latest Brainstorm Cell insider transactions to see recent buying and selling activity by company executives and directors.
Check the Brainstorm Cell congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The BCLI stock price chart above shows Brainstorm Cell’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Brainstorm Cell technical analysis for RSI, moving averages, and more.
See the stocks similar to Brainstorm Cell section on this page for companies in the same industry ranked by market cap and AI Score.
